基于18F-FDG-PET/CT的新辅助化疗期间总代谢肿瘤体积变化可预测晚期上皮性卵巢癌的结局
该研究纳入29例初治不可手术的FIGO III/IV期上皮性卵巢癌患者,在新辅助化疗前后行18F-FDG-PET/CT,评估总代谢肿瘤体积(MTV)变化对原发治疗结局和无进展生存期(PFS)的预测价值。结果显示,新辅助化疗后MTV及MTV下降幅度与治疗结局和PFS相关,MTV下降<85%可识别进展或稳定疾病患者。
要点
- 新辅助化疗前后中位总MTV分别为352 cm3和51 cm3,中位MTV下降89%。
- 新辅助化疗后MTV与MTV下降幅度均与治疗结局及PFS相关。
- MTV下降<85%可识别进展或稳定疾病患者,敏感度70%、特异度78%、AUC 0.79。
核心结论
- 18F-FDG-PET/CT有助于新辅助化疗反应评估。
- 新辅助化疗期间总MTV下降<85%的患者可能是二线化疗和临床试验的候选者,而非间隔减瘤手术。
研究设计与样本
- 研究纳入29例初治不可手术的晚期FIGO III/IV期上皮性卵巢癌患者。
- 患者在新辅助化疗前后接受18F-FDG-PET/CT检查。
- 比较新辅助化疗前后总MTV及MTV下降百分比与原发治疗结局和PFS的关系。
- 采用ROC分析确定识别原发治疗结束时进展或稳定疾病(PD/SD)的MTV下降最佳阈值。
- 多因素分析纳入残留肿瘤(0/>0)、FIGO分期(III/IV)和MTV下降与PFS的关系。
主要发现
- 新辅助化疗前中位总MTV为352 cm3(范围150至1322 cm3),新辅助化疗后中位总MTV为51 cm3(范围0至417 cm3)。
- 新辅助化疗期间中位MTV下降为89%(范围24%至100%)。
- 新辅助化疗后MTV与治疗结局相关(p=0.007),MTV下降与治疗结局相关(p=0.001)。
- 新辅助化疗后MTV与PFS相关(p=0.005),MTV下降与PFS相关(p=0.005)。
- 多因素分析中,MTV下降(p=0.002)和FIGO分期(p=0.003)是与PFS相关的统计学显著变量。
关键数值与推荐
- MTV下降<85%识别PD/SD患者,敏感度70%,特异度78%,AUC 0.79。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the predictive potential of total metabolic tumor volume (MTV) reduction during neoadjuvant chemotherapy (NACT) with 18F-FDG-PET/CT in an advanced FIGO stage III/IV epithelial ovarian cancer (EOC) patient cohort. METHODS: Twenty-nine primarily inoperable EOC patients underwent 18F-FDG-PET/CT before and after NACT. The pre- and post-NACT total MTV, in addition to the percentage MTV reduction during NACT, were compared with primary therapy outcome and progression-free survival (PFS). ROC-analysis determined an optimal threshold for MTV reduction identifying patients with progressive or stable disease (PD/SD) at the end of primary therapy. A multivariate analysis with residual tumor (0/>0), FIGO stage (III/IV) and MTV reduction compared to PFS was performed. The association between MTV reduction and overall survival (OS) was evaluated. RESULTS: The median pre- and post-NACT total MTV were 352 cm3 (range 150 to 1322 cm3) and 51 cm3 (range 0 to 417 cm3), respectively. The median MTV reduction during NACT was 89% (range 24% to 100%). Post-NACT MTV and MTV reduction associated with primary therapy outcome (MTV post-NACT p = 0.007, MTV reduction p = 0.001) and PFS (MTV post-NACT p = 0.005, MTV reduction p = 0.005). MTV reduction <85% identified the PD/SD patients (sensitivity 70%, specificity 78%, AUC 0.79). In a multivariate analysis, MTV reduction (p = 0.002) and FIGO stage (p = 0.003) were statistically significant variables associated with PFS. MTV reduction during NACT corresponded to OS (p = 0.05). CONCLUSION: 18F-FDG-PET/CT is helpful in NACT response evaluation. Patients with total MTV reduction <85% during NACT might be candidates for second-line chemotherapy and clinical trials, instead of interval debulking surgery.
引用
- Vallius T, Hynninen J, Kemppainen J, et al. 18F-FDG-PET/CT based total metabolic tumor volume change during neoadjuvant chemotherapy predicts outcome in advanced epithelial ovarian cancer. Eur J Nucl Med Mol Imaging. 2018. PMID: 29476227. doi:10.1007/s00259-018-3961-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。